The antibody, ISB 2001, is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) ...

Glenmark Pharmaceuticals' shares surged 10% to an all-time high of ₹2,094 following the announcement of an exclusive ...

Ichnos Glenmark Innovation & AbbVie ink exclusive global licensing agreement for ISB 2001: New York Saturday, July 12, 2025, 12:00 Hrs [IST] IGI Therapeutics SA, a wholly owned su ...

Glenmark Pharma's exclusive licensing deal with AbbVie for ISB-2001 could be transformative, offering significant upside ...

Regardless of the bearish sentiment prevailing across the Indian stock market today, Glenmark Pharma shares skyrocketed 16% ...

The stock was the top percentage gainer on the Nifty Pharma index, which traded 0.3% higher compared to a 0.8% loss in the ...

The shares of the prominent pharmaceutical company broke the upper band, gained up to 15 percent in today's trading session after the company's subsidiary of Ichnos Glenmark Innovation Inc., entered ...

The investment landscape is shifting as companies show resilience and innovation, prompting investors to reassess portfolios. AbbVie, Boeing, Oracle, and Joby Aviation mentioned as potential ...

Glenmark Pharmaceuticals Ltd's shares soared over 14% after announcing a deal with AbbVie worth up to USD 2 billion. The ...

Shares of Glenmark Pharmaceuticals Ltd ended 14.51 per cent higher on Friday after the firm announced signing an up to USD 2-billion deal with AbbVie to commmercialise its underdevelopment drug aimed ...

The S&P BSE Sensex also ended lower, falling 0.83% to close at 82,500 points, and registered a weekly loss of over 1.06%.